A drug that commonly prescribed to treat anemia in heart failure patients may not improve the patients health or reduce the risk of death from heart failure, according to a study presented at the American College of Cardiologys annual meeting in March. The study, conducted by researchers at the University of Gothenburg, Sweden, Cleveland Clinic and many other centers, found that patients who took the drug darbepoetin alfa experienced similar clinical outcomes as those who took a placebo. The study involved more than 2,000 anemic heart failure patients in 33 countries.
To continue reading this article or issue you must be a paid subscriber.
Sign in
